Small Cap Value Report (Tues 26 Sept 2023) - IQG, PCIP, BAG, VID, REDD
Good morning from Graham and Paul!
Explanatory notes -
A quick reminder that we don’t recommend any stocks. We aim to review trading updates amp; results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it’s anybody’s guess what direction market sentiment will take amp; nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.
We stick to companies that have issued news on the day, with market caps (usually) between £10m and £1bn. We usually avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).
A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments are welcomed – please be civil, rational, and include the company name/ticker, otherwise people won’t necessarily know what company you are referring to.
What does our colour-coding mean? Will it guarantee instant, easy riches? Sadly not! Share prices move up or down for many reasons, and can often detach from the company fundamentals. So we’re not making any predictions about what share prices will do.
Green (thumbs up) – means in our opinion, a company is well-financed (so low risk of dilution/insolvency), is trading well, and has a reasonably good outlook, with the shares reasonably priced.
Amber – means we don’t have a strong view either way, and can see some positives, and some negatives. Often companies like this are good, but expensive.
Red (thumbs down) – means we see significant, or serious problems, so anyone looking at the share needs to be aware of the high risk. Sometimes risky shares can produce high returns, if they survive/recover. So again, we’re not saying the share price will necessarily under-perform, we’re just flagging the high risk.
There’s far too much for us to cover everything today, but this is what we’ll attempt to review -
Summaries
IQGeo (LON:IQG) – down 8% y’day to 267p (£164m) – Interims – Paul – AMBER/RED
Very rapid growth from this interesting software company. Looks set to have a breakthrough year into profit (at last). However, the balance sheet concerns me, in particular excessive and overdue receivables, which needs explaining/resolving, as it could sow the seeds for a future write-off. Hence I’m wary because of this specific issue, and valuation looks like it’s run ahead of things a bit.
PCI- PAL (LON:PCIP) - 49p pre-market (£32m) – Wins patent case – Paul – AMBER/GREEN
“Total victory” declared PCIP last night, in its UK High Court patent case. Expect a strong rebound in share price today. Well done to holders, this removes a big uncertainty and cash drain.
A G Barr (LON:BAG) – down 1% to 486p – Interim Results (in line) – Graham – GREEN
This Scottish soft drinks maker confirms it’s trading in line with recently upgraded expectations. It grabs volume and market share in an industry struggling with high inflation and lower volumes. I remain a fan of Barr, despite the significant sector challenges it faces.
Videndum (LON:VID) - down 33% to 370p (£172m) – Interims – Paul – RED
Another profit warning, but worse than that, it says an equity raise may now be needed to ease the excessive bank debt. There’s also a worrying “material uncertainty” over going concern. We’ve previously warned here earlier this year about the problem level of bank debt. I see this as too risky until it’s refinanced, so uninvestable for now.
Redde Northgate (LON:REDD) – up 2% to 340p (£773m) – AGM Statement – Paul – GREEN
A positive-sounding update, with demand still outstripping supply of vehicles, and residual values remaining strong. That won’t last forever of course. So the impressive value stats (a yield above the PER, and full asset backing) may not last at these levels. Extremely tempting to pick up a few at this attractive valuation, I reckon.
Paul’s Section: IQGeo (LON:IQG)
Down 8% y’day to 267p (£164m) – Interims – Paul – AMBER/RED
IQGeo Group plc (AIM: IQG), a market leading provider of geospatial productivity and collaboration software for the telecoms and utility network industries, is pleased to announce its interim results for the six months ended 30 June 2023.
I haven’t looked at this company for over 5 years, when it used to be called Ubisense, but always seemed to be promising jam tomorrow, and generating losses, hence I lost interest.
Things seem to have moved on considerably since then, with a big rise in revenues, although still loss-making, and a multibagging share price.
It recently caught my eye when a fund manager was raving about it on a podcast, saying how interesting and useful its software is for utilities companies to track and identify their infrastructure. So I made a mental note to take a look at the next set of numbers, which were published yesterday (interim results).
The Stocko graphs below show that it could be about to break into significant profitability (at long last) -
Key numbers for H1 results (to June 2023) –
Very strong revenue growth, up 124% (83% organic) to £20.5m in H1
Exit ARR (annual recurring revenue) is £16.9m, so less than half revenues are recurring (only 35% in H1), which is quite low for a software company.
Costs are also rising fast, which blunts the operational gearing.
Comsof acquisition is going well.
Outlook – in line exps, says outlook is very positive.
Adj EBITDA £2.7m (up strongly from £0.2m in H1 LY)
Loss before tax of £(177)k, slight improvement from £(483)k in H1 LY
Here’s the reconciliation from EBITDA to the small PBT loss (bold is this year, unbold is LY comparative)-
Balance sheet - I do enjoy it when I find a problem balance sheet, and there is definitely a problem here.
NAV of £21.8m is nearly all intangible assets (of £20.1m), so NTAV is threadbare at only £1.7m. To be fair, software companies don’t usually need much in assets, as there’s negligible fixed assets to finance, and customers often pay up-front. Even so, for £164 market cap company, I would have liked at least some asset backing.
Cash of £6.9m is OK, although trade creditors contains £8.2m deferred income (the amount customers have paid up-front).
This is the problem – receivables (unpaid customer invoices) looks far too high at £13.9m. This item should usually be about 60 days sales + VAT. So c.£8.2m would be about right. There’s actually another £5.7m over and above what’s reasonable. I cannot find any explanation as to why receivables is so high. So I looked at the 2022 Annual Report, and this also showed excessive receivables, with the notes showing that £908k was more than 90 days overdue, and £7.0m was 0-90 days overdue. It alluded to customers having financial problems, hence not having paid their invoices on time.
It looks as if the position has not been resolved in the latest interim numbers.
So we need to find out who these late-paying customers are, why they’re paying late (it might be disputed invoices, not necessarily financial stress), and whether it has since been resolved.
The danger is that IQG might be forced into making bad debt provisions against receivables, which would essentially mean that some previously reported profit was invalid.
Hence we have here the possible seeds for a future profit warning, if receivables write-offs are required. For this reason, I’m wary of this share, and wouldn’t invest unless the excessive receivables issue has been explained and resolved.
Paul’s opinion – looks an interesting company, but I think the market cap might have overshot on the upside for the time being. Also I would need to see the issue of excessive receivables explained/resolved, as that’s too large a risk factor at present, the way I read the numbers.
That said, the very rapid growth does look exciting
PCI- PAL (LON:PCIP)
49p pre-market (£32m) – Wins patent case – Paul – AMBER/GREEN
“Total victory” thundered PCIP last night in an RNS, concerning its expensive amp; protracted UK High Court battle over patents with competitor Sycurio. More details will follow shortly.
Paul’s opinion – this seems excellent news for PCIP, since the patent case cast a cloud over the company, and was absorbing a lot of fairly scarce cash. Therefore to remove this uncertainty, and financial drag (not to mention management time) is a big boost for the shares.
I think there was also a US action ongoing, so am not sure if/how that is affected by the UK court victory for PCIP. Also what happens with costs, who pays those?
It’s fun to guess what the share price might do (writing this at 07:50), I’m going to say a decent jump could be on the cards, maybe 60-75p today? That looks justified on fundamentals. Anything above that would be getting a little excessive I think. After all, PCIP is still very small, and modestly loss-making, albeit with strong organic growth, so let’s not get too euphoric!
Videndum (LON:VID)
Down 33% to 370p (£172m) – Interims – Paul – RED
Videndum plc (“the Company” or “the Group”), the international provider of premium branded hardware products and software solutions to the content creation market, announces its results for the half year ended 30 June 2023.
Chairman announces he’ll be stepping down at the 2024 AGM. The company seems to think he’s done a good job, but I doubt many shareholders would agree with that.
H1 figures are poor, with problems driven by macro, customer de-stocking, and the writers’ amp; actors strikes in Hollywood deferring film/TV projects and hence purchases of equipment by customers.
Revenues in H1 are down 25% at £165m
Adj PBT down 65% to £10.1m
Statutory loss before tax is very large, at £(50)m, so about £60m of adjustments there, mostly relating to discontinued operations – looks like something quite big went wrong then.
All the above is survivable, understandable, even. However this is the big problem (as we flagged here on 3 May 2023 – an acquisition splurge, funded by taking on excessive debt, now leaves the company in a precarious position.
Net debt of £216.1m is clearly way too high, although this includes £36.2m of lease liabilities, so net bank debt is £180m. It is close to covenant limits, but these have been relaxed for Dec 2023, so no immediate crisis.
Equity raise – here’s the bombshell that, for now, makes this share uninvestable for me – why take the solvency/dilution risk at this stage? I’d rather wait until after it’s refinanced, then look at it fresh, and maybe then benefit from a recovery in trading once the strikes have been resolved -
We have excellent relationships with our banks and the Group is proactively working to reduce leverage and recapitalise the business, which may require an equity raise.
Going concern – is bad, a material uncertainty -
As stated in note 1, these events or conditions, along with the other matters as set forth in note 1 to the condensed set of financial statements, indicate that a material uncertainty exists that may cast significant doubt on the company’s ability to continue as a going concern.
Outlook – in a word, uncertain -
Encouraging news about the strikes, however, it is not clear when productions will restart, therefore there is a wide range of potential outcomes for FY 2023, and it is difficult to provide financial guidance. Nonetheless, when productions restart, the Group remains well positioned and we expect to benefit from a significant recovery in revenue
Balance sheet – is weak, with nil NTAV.
Obviously far too much bank debt too, which was a conscious decision management wrongly took, to acquire too many companies, using too much debt.
If even a humble shares blogger foresaw that management had overdone the debt-fuelled acquisitions, it does make me wonder why they did this? Surely it’s just recklessness, and a failure to plan for any downside scenarios?
My opinion – sorry for any subscribers here holding this share. I can understand that the various factors it mentions have hurt performance this year, and there should be a recovery in due course.
However, the weak, overly indebted balance sheet, means it doesn’t have the financial strength to be able to ride out a bad patch. This was caused by poor management decisions, to over-expand, using too much debt.
It’s specifically told us that it might need an equity raise. I’d say that’s almost a certainty actually. Who knows what terms that might be done on? The discount could be modest, or it could be huge, it’s total guesswork at this stage. So I see existing small shareholders as potential lambs to the slaughter, if whoever refinances it with fresh equity demands their pound of flesh.
The beauty is that small shareholders can sell up, and watch from the sidelines if we want to, a massive advantage over institutions, who are high and dry with their large stakes.
We’ll take a fresh look once it’s refinanced, but for now, I see this as much too risky.
Redde Northgate (LON:REDD)
Up 2% to 340p (£773m) – AGM Statement – Paul – GREEN
Strong start to FY2024 with good momentum and healthy demand
Redde is the no fault accident vehicle credit hire company that works co-operatively with insurance companies. Northgate is the white van hire business in UK amp; Spain. Simple to explain really, unless you’re the company itself, which comes out with this meaningless twaddle -
Redde Northgate plc (LSE:REDD), the leading integrated mobility solutions platform providing services across the vehicle lifecycle…
Today’s update sounds good – key points -
FY 4/2024 has “started very well”, strong trading, healthy demand.
Rentals – demand outstripping (improving) supply still.
Vehicle residual values still high, giving disposal profits.
Redde – new client win, and “robust pipeline”.
Share buyback – done £3.6m of £30.0m planned.
Debt maturities comfortable, out to 2031.
Dividends – final 16.5p, giving total 24.0p (yield 7.1%)
Paul’s opinion – this is looking very tempting again as an entry point. We know that profits are likely to fall at some point in future, as vehicle residual values normalise, so doing some sums to estimate how that might pan out is probably the key thing to research yourself. I don’t have any access to broker notes.
These value stats look highly appealing, especially the yield that’s higher than the PER, and full net tangible asset backing for the market cap. Chips and rice, as they say!
Note the very high StockRank too -
Graham’s Section: A G Barr (LON:BAG)
Share price: 486p (-1%)
Market cap: £544m
This is the soft drinks company whose leading brand is IRN-BRU. The complete list of brands can be found here (including Snapple, owned by Keurig Dr Pepper, which Barr has the right to distribute).
I covered Barr’s ahead-of-expectations trading update in August, and I’ve been positive on the stock in recent years.
The share price has been steady. Here’s the three-year chart:
And now onto today’s H1 results, which come with the headline:
Strong first half performance – confident of delivering full year profit in line with recently increased market expectations.
I’ve highlighted some of the bits I find most important:
Total revenues are up 33% due to the acquisition of Boost Energy Drinks, but the 10.4% like-for-like growth is proof of a strong underlying performance.
I’m also enthused by the 12.6% growth in reported PBT, even if it’s growing more slowly than total revenues.
The decline in adjusted operating profit margin reflects “the impact of current lower margin Boost business model”.
However, they also say that they “chose not to pass on the full impact of cost inflation to customers in order to remain focused on offering consumers great value”. I’m always sceptical when companies say that they haven’t charged more out of generosity to their customers! But I believe that Barr has already raised prices significantly in the post-Covid era, and they may have felt that further large price increases were unnecessary.
Cash - Barr bought Boost for £20m and also spent a few million pounds increasing its ownership of Moma Foods, so this goes a low way towards explaining the fall in the company’s cash balance over the past year. But they still have a very healthy war chest for future acquisitions or internal capex.
I also note that the company says earnings per share would have grown 12% if not for the higher corporate tax rate. So I wouldn’t be overly concerned about the small decline in EPS.
CEO comment:
“We have made significant financial and strategic progress in the first half and have exciting plans in place for the balance of the year to sustain our growth momentum.
We remain confident in delivering a full year profit performance in line with our recently increased market expectations and are well positioned to deliver strong shareholder returns for the long-term.”
As we’ve previously noted, this CEO is planning to retire over the next year – I’m expecting a very orderly transition as the company has plenty of time to find his successor.
Comments on the soft drinks industry are relevant for some other shares we cover here, including the likes of Nichols (LON:NICL) and Britvic (LON:BVIC) etc. The UK soft drinks market has increased in value by 8% in H1, even though volumes were down 4.2%. This implies double-digit price inflation. Barr says that they gained “both value and volume market share”. If that has come at the cost of a slightly reduced operating profit margin, perhaps it’s worth it!
Outlook excerpt:
We have strong plans in place across the business for the balance of the year to support our growth momentum. In August we communicated our expectation of delivering a full year profit performance marginally above the top end of analyst consensus. Despite the extended period of poor weather across the summer, we remain confident in delivering in line with these revised market expectations.
Graham’s view
There’s no reason to change my view on A.G. Barr today – I’m a long-term fan of this one, and it remains attractively priced in my opinion:
There are some long-term concerns about the soft drinks industry:
-
Sugar tax (since 2018) – a sign of things to come, with increasing taxation and regulation of sugary drinks?
-
Packaging – the deposit return scheme will complicate matters if and when it is introduced (possibly in late 2025)
-
Competition – there are new entrants to the soft drinks market, particularly from popular YouTubers (e.g. Prime).
So for a variety of reasons, you could argue that Barr should trade on an average mid-teens earnings multiple, i.e. at its current valuation. However, I’ll stick to my guns and continue to give Barr the thumbs up, as I do consider it to be an above-average company trading at an average price.
Source: https://www.stockopedia.com/content/small-cap-value-report-tues-26-sept-2023-iqg-pcip-bag-vid-redd-976198/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
